Melbourne, Australia, March 20, 2024 -- Leading digital health company Adherium Limited (ASX:ADR) is pleased to announce the first patient has been enrolled in a newly cemented research partnership between US Intermountain Health and CareCentra using Hailie® sensors to monitor key physiological data.
The focus of the collaboration between Adherium, CareCentra and Intermountain Health is to conduct a large scale real-world chronic respiratory disease clinical study, to examine and demonstrate the benefit of embedding e-health systems to improve patient outcomes and lower health care costs.
Study preparations included a purchase order for 4,000 Hailie® sensors. The iCare study will involve 2,500 patients across five Intermountain facilities over two years to transform respiratory management for chronic obstructive pulmonary disease (COPD) and asthma patients.
The study leverages Intermountain’s network of respiratory clinics, physicians and hospitals; CareCentra’s leading behavioural science and AI capabilities; and Adherium’s Hailie remote sensor technology – all aimed at providing a clinical assessment of the health and economic benefits of e-health management of chronic respiratory disease.
The study will use Adherium’s next generation Hailie sensors to provide real-time, remote data to the CareCentra AI which continuously monitors patient risk levels with a complex algorithm of data points, including signals of when and how patients are using prescribed inhaler medication from the Hailie device. These data points provided by Adherium’s Hailie remote sensor technology allow the CareCentra platform to assess health risk, recommend behavioral shifts in technique or adherence, and if problems persist, alert Intermountain Health for timely interventions and tailored treatments to improve health outcomes. These efforts can greatly reduce adverse events and hospital admissions.
At a glance
- Company
- Adherium Limited
- Ticker
- ASX: ADR
- Announcement
- Partnership
- Location
- Melbourne, Australia
Key figures
- Hailie sensors ordered
- 4,000
- Planned study participants
- 2,500
- Intermountain facilities
- five
- Study duration
- two years
People
- Paul MastoridisAdherium CEO
- Peter CrossnoIntermountain Health Associate Medical Director for Pulmonary and Respiratory Care
- Vasant KumarCareCentra CEO
Products and programs
Hailie sensors accurately monitor peak inspiratory flow, inspiratory flow duration, inhaled volume and other metrics ensuring a patient’s prescribed medication effectively reaches their lungs. Hailie® is the only US FDA 510(k) cleared, drug-agnostic digital sensor providing physiological data insights on inhaler technique.
Adherium CEO, Dr. Paul Mastoridis, said: “This is a groundbreaking partnership that accelerates the trajectory of Adherium both clinically and financially in line with our recent pivot to full commericalisation in the US through large scale strategic partnerships."
“The iCARE study will provide further clinical validation of Hailie’s next generation sensors and measure behavioural shifts and healthcare cost reductions, to validate how Hailie enables a new value-based e-healthcare model that benefits everyone from patients and doctors to hospitals and insurers.”
Intermountain Health Associate Medical Director for Pulmonary and Respiratory Care, Peter Crossno, M.D., Ph.D., said: “Patients can struggle with their COPD and asthma and medication adherence more than we know. The iCare model, integrating Adherium data within the CareCentra AI platform and user-friendly app, can be an early warning system and provide immediate feedback and trends to patients and their carers on adherence, inhaler technique, triggers and more.”
CareCentra’s behavior shaping platform and AI uses a range of data points, including expiratory flow rate, respiratory rate, oxygen saturation, heart rate, inspiratory flow rate, and date/time stamps of medication adherence to monitor rising health risk and nudge both patient and respiratory care teams to control exacerbations and improve outcomes. The iCare study’s goal is to leverage cutting edge digital health technology and respiratory biomarkers to identify rising risks and engage patients and providers in co-managing that risk, improving outcomes and reducing healthcare costs.
CareCentra CEO, Vasant Kumar, said: “Intermountain Health and CareCentra have a long-standing relationship developing healthcare innovation, research and technology to fundamentally redesign how patients manage chronic and acute conditions. The CareCentra AI remotely monitors, triages and alerts care teams for just-in-time intervention, to help prevent hospitalisation in a range of chronic and acute conditions. The iCare study is an important validation of this approach in COPD and asthma practice and at scale.”
If you detect any issues, problems, or errors in this press release content, kindly contact [email protected] to notify us (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). We will respond and rectify the situation in the next 8 hours.
In brief
Adherium Limited says the first patient has entered the iCare study, a collaboration with Intermountain Health and CareCentra focused on chronic obstructive pulmonary disease and asthma management. The study will use Adherium’s Hailie sensors to collect respiratory and inhaler-use data, which CareCentra’s AI platform will assess for signs of rising health risks. The partners intend to evaluate whether embedding digital health tools in care can improve patient outcomes and reduce healthcare costs. The study is planned to involve 2,500 patients at five Intermountain facilities over two years. Preparations included an order for 4,000 Hailie sensors. The release describes the sensors as measuring respiratory indicators and medication use, with data intended to help patients and care teams respond to adherence or technique concerns.
Key takeaways
- Adherium reports that the first patient has enrolled in the iCare respiratory management study.
- The study will involve 2,500 patients at five Intermountain facilities over two years.
- CareCentra’s AI platform will assess data from Hailie sensors for potential health risks.
- Preparations included a purchase order for 4,000 Hailie sensors.
